Search
Bevirimat
go.drugbank.com/drugs/DB06581InvestigationalIt is not currently FDA-approved, but is undergoing clinical trials conducted by the pharmaceutical company Panacos.
Trimethadione
go.drugbank.com/drugs/DB00347ApprovedWithdrawnAn anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378)
Epratuzumab
go.drugbank.com/drugs/DB04958InvestigationalEpratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as...
Proxalutamide
go.drugbank.com/drugs/DB16065InvestigationalProxalutamide is under investigation in clinical trial NCT03899467 (The Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer).
Pirlindole
go.drugbank.com/drugs/DB09244ExperimentalIt was developed and is currently used as an antidepressant in Russia. Its chemical structure is similar to metralindole, and it also shares pharmacological properties with this drug.
Omaveloxolone
go.drugbank.com/drugs/DB12513ApprovedInvestigationalOmaveloxolone (RTA-408) is a semisynthetic oleanane triterpenoid with antioxidant and anti-inflammatory properties. Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mit...
Imiglucerase
go.drugbank.com/drugs/DB00053ApprovedInvestigationalThe modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues.
Abciximab
go.drugbank.com/drugs/DB00054ApprovedWithdrawnIt also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.
Roxadustat
go.drugbank.com/drugs/DB04847ApprovedInvestigationalIt works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transcription factor that stimulates red blood cell production in response to low oxygen levels.
Ximelagatran
go.drugbank.com/drugs/DB04898ApprovedWithdrawnIn 2006, its manufacturer AstraZeneca announced that it would not attempt to market ximelagatran after reports of hepatotoxicity (liver damage) during trials, and to discontinue its distribution in countries